Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Amortization of Deferred Charges: 2009-2024

Historic Amortization of Deferred Charges for Ligand Pharmaceuticals (LGND) over the last 14 years, with Dec 2024 value amounting to $486,000.

  • Ligand Pharmaceuticals' Amortization of Deferred Charges rose 233.58% to $447,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $880,000, marking a year-over-year increase of 122.78%. This contributed to the annual value of $486,000 for FY2024, which is 102.50% up from last year.
  • Ligand Pharmaceuticals' Amortization of Deferred Charges amounted to $486,000 in FY2024, which was up 102.50% from $240,000 recorded in FY2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Amortization of Deferred Charges peaked at $23.1 million during FY2020, and registered a low of $240,000 during FY2023.
  • Over the past 3 years, Ligand Pharmaceuticals' median Amortization of Deferred Charges value was $486,000 (recorded in 2024), while the average stood at $486,667.
  • In the last 5 years, Ligand Pharmaceuticals' Amortization of Deferred Charges crashed by 95.60% in 2022 and then skyrocketed by 102.50% in 2024.
  • Ligand Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $23.1 million in 2020, then declined by 27.67% to $16.7 million in 2021, then plummeted by 95.60% to $734,000 in 2022, then crashed by 67.30% to $240,000 in 2023, then surged by 102.50% to $486,000 in 2024.